knowledge -WSS

knowledge

author：comprehensive 2025-08-12 06:43:36 - browse：97564

Medicare and money photo illustration. — Adobe

WASHINGTON — A week after the Food and Drug Administration granted full, traditional approval to a new Alzheimer’s treatment, insurers are finalizing their plans to cover it as well as associated scans and diagnostic tests.

Medicare will cover most patients eligible for Leqembi, a new treatment developed by Eisai and Biogen to help slow the progression of Alzheimer’s disease. The drug, which has modest benefits, has potentially serious side effects for some patients including brain swelling and bleeding.

Medicare told STAT that it would cover brain scans and genetic testing that will help screen for and monitor potential side effects. Medicare already covers one amyloid PET scan per lifetime, but the agency is reconsidering that policy and plans to release a new proposed policy “soon,” an agency spokesperson said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Longer MASH drug regimen improved liver, Akero study finds

knowledge

WSS

Readout Newsletter: BridgeBio, Akero, and human embryo models

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

The Bio Revolution is changing business and society

A new approach to psychiatric drug development

Change Healthcare: What is it, why does its cyberattack matter?

knowledge

knowledge

hotspot

As demand for Covid shots wanes, Moderna seeks its next success

U.S. death rates show how politics are affecting public health

Heart attack and stroke risk calculators need revising

Medicare drug price negotiation continues, as pharma counteroffers

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Congress: Prevent baby formula shortages by passing a new bill

State Dept. review finds Biden bears some blame for Afghanistan failures

$1 billion proposal to grow Boston, Massachusetts biotech

Cancer drug shortages should be causing more outrage

Stroke rates rising, especially in working

Wikipedia

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

Lawsuit challenges CMS nursing home minimum staffing rule

Stroke rates rising, especially in working

Stroke rates rising, especially in working

Medicare drug price negotiation hearing pits pharma v Biden admin

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Wikipedia

focus

knowledge

explore